What's in Hikma Pharmaceuticals LLC's pipeline?

Hikma Pharmaceuticals LLC has 3 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Hikma Pharmaceuticals LLC's portfolio?

Top competitors by shared drug class: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Biocad, Celltrion, Centocor, Inc., Children's Memorial Health Institute, Poland.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hikma-pharmaceuticals-llc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Hikma Pharmaceuticals LLC — Portfolio Competitive Intelligence Brief

Hikma Pharmaceuticals LLC pipeline: 1 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Biosimilar Infliximab	Biosimilar Infliximab	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)	Immunology / Rheumatology / Gastroenterology

Therapeutic area mix

Other · 2
Immunology / Rheumatology / Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class
Biocad · 1 shared drug class
Celltrion · 1 shared drug class
Centocor, Inc. · 1 shared drug class
Children's Memorial Health Institute, Poland · 1 shared drug class
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · 1 shared drug class
Hanyang University Seoul Hospital · 1 shared drug class
AbbVie (prior sponsor, Abbott) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hikma Pharmaceuticals LLC:

Cite this brief

Drug Landscape (2026). Hikma Pharmaceuticals LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hikma-pharmaceuticals-llc. Accessed 2026-05-16.